- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02548559
Sublingual Cannabidiol for Anxiety
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cannabis has been used for medicinal purposes across many cultures for a range of disorders for thousands of years. The plant is comprised of a variety of components, such as phytocannabinoids, which include (among others) the major intoxicating constituent of cannabis, delta-9 tetrahydrocannabinol (THC), and cannabidiol (CBD), a major non-intoxicating constituent of cannabis. Increasing evidence indicates that CBD in particular may have significant medicinal properties and benefits; experimental studies in both animals and humans have demonstrated that CBD can act as an anticonvulsant, antipsychotic, and muscle relaxant. Several studies have demonstrated that CBD produces acute anxiolytic effects in animals and humans, although thus far no clinical trials of CBD have been conducted in patients with anxiety. As a growing number of states are legalizing medical cannabis, a gap exists in the scientific literature regarding the effects of CBD on anxiety.
This investigation is composed of two stages. Stage 1 is comprised of a four-week, open-label clinical trial of a high-CBD containing compound in individuals with anxiety. Participants will be pre-screened by phone in order to evaluate their eligibility for the study. If approved, participants will come to the hospital for a baseline/screening visit, and will complete a structured clinical interview, clinical and quality of life questionnaires, and cognitive assessments. Enrolled participants will be given CBD solution to use for the duration of the study; participants will be instructed to self-administer 1 milliliter (ml) of the tincture under the tongue three times per day for four weeks. Throughout the treatment period, participants will return to the hospital on a weekly basis to complete questionnaires about their mood and quality of life. Participants will also return to the hospital for a final visit after four weeks of treatment to complete additional questionnaires and cognitive assessments. Stage 1 of the study was completed in early 2020.
Stage 2 of the study is a double-blind clinical trial of this solution in patients with anxiety. This double-blind trial began after the open-label trial was completed. In the same manner as the open-label trial, participants will be pre-screened by phone, and approved participants will come to the hospital for a baseline/screening visit to complete a structured clinical interview, questionnaires, and cognitive assessments. Eligible participants will also have the option to complete an hour-long MRI scan at the baseline and final visits. Enrolled participants will receive either full-spectrum CBD solution, single-compound CBD solution, or placebo solution to self-administer throughout the four week treatment period, as described above. Participants will return to the hospital weekly during the treatment period to complete questionnaires about their mood and quality of life. Participants in this stage of the study will also return for a final visit after four weeks of treatment to complete additional questionnaires, cognitive assessments, and an optional hour-long MRI scan. We are currently recruiting for Stage 2 of the study.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Rosemary Smith, M.S.
- Phone Number: 617-855-3338
- Email: CBDstudy@mclean.harvard.edu
Study Locations
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478-9106
- Recruiting
- McLean Hospital Brain Imaging Center
-
Contact:
- Staci Gruber, PhD
- Phone Number: 617-855-2762
- Email: gruber@mclean.harvard.edu
-
Principal Investigator:
- Staci A Gruber, Ph.D.
-
Sub-Investigator:
- David P Olson, M.D., Ph.D.
-
Sub-Investigator:
- Scott E Lukas, Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 or older
- Native English speaker or acquired English prior to age 5
- Provides informed consent
- Endorses moderate or severe anxiety at the screening visit
Exclusion Criteria:
- Non-native English speakers
- Estimated IQ < 75
- Pregnancy
- Presence of serious medical illness, including liver or kidney disease, neurological disorder, or certain psychiatric disorders
- History of head injury or loss of consciousness >5 minutes
- Current use of cannabis or cannabinoid products >1x/month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Full-Spectrum Cannabidiol
1 ml of full-spectrum sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
|
Full-Spectrum Cannabidiol; total daily dose of 30 mg.
|
Experimental: Single-Compound Cannabidiol
1 ml of single-compound sublingual cannabidiol solution (10 mg/ml CBD) administered three times per day (TID) for four weeks.
|
Single-Compound Cannabidiol; total daily dose of 30 mg.
|
Placebo Comparator: Placebo
1 ml of placebo solution administered three times per day (TID) for four weeks.
|
Placebo solution.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Self-Reported Anxiety as Assessed by the Beck Anxiety Inventory (BAI)
Time Frame: Week 1, Week 2, Week 3, Week 4
|
The BAI is a 21-item self-report measure used to rate subjective, somatic, and panic-related symptoms of anxiety on a scale of 0 to 3 (higher scores indicating more anxiety).
|
Week 1, Week 2, Week 3, Week 4
|
Change from Baseline in Anxiety Assessed by the Overall Anxiety Severity and Impairment Scale (OASIS)
Time Frame: Week 1, Week 2, Week 3, Week 4
|
The OASIS is a brief 5-item measure used to evaluate the functional impairment cause by anxiety that will be given on a weekly basis; the frequency and intensity of anxiety, as well as the degree of avoidance and interference with work and social function are rated on a scale of 0 to 4 (higher scores indicating more anxiety).
|
Week 1, Week 2, Week 3, Week 4
|
Change from Baseline in Self-Reported Anxiety Assessed by the State-Trait Anxiety Inventory (STAI)
Time Frame: Week 1, Week 2, Week 3, Week 4
|
This self-report measure is comprised of two 20-item scales, with a range of four possible responses from 1 to 4 (higher scores indicating more anxiety), and differentiates between the more temporary condition of "state" anxiety and the more general quality of "trait" anxiety.
|
Week 1, Week 2, Week 3, Week 4
|
Change from Baseline in Anxiety Measured by the Hamilton Anxiety Scale (HAM-A)
Time Frame: Week 1, Week 2, Week 3, Week 4
|
This observer-rating 14-item scale is administered in the form of an interview, and allows information from multiple sources to influence ratings (i.e.
subject report, examiner's observation), and has been shown to be reliable index of clinical state.
A range of 5 possible responses (0-4, not present-very severe) are possible for each item.
|
Week 1, Week 2, Week 3, Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in Depressive Symptoms Assessed by the Beck Depression Inventory (BDI)
Time Frame: Week 1, Week 2, Week 3, Week 4
|
The BDI is a 21 item-self-report measure that can be used to assess the severity of depression.
Each item on the BDI relates to a symptom of depression and is rated by the subject using a 0-3 scale (higher scores indicating increased severity).
|
Week 1, Week 2, Week 3, Week 4
|
Change from Baseline in Sleep Quality Assessed by the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Week 1, Week 4
|
The PSQI contains 19 self-rated questions that assess sleep quality and disturbance over the previous 1-month period.
The 19 items yield seven component scores such as sleep latency, sleep duration, and daytime dysfunction, which are then summed to generate a global score (higher scores indicating decreased sleep quality).
|
Week 1, Week 4
|
Change from Baseline in Mood Measured by the Profile of Mood States (POMS)
Time Frame: Week 1, Week 2, Week 3, Week 4
|
Comprised of 72 adjectives commonly used to describe mood states, subjects are asked to indicate how they feel at that moment in relation to each of the adjectives using a five point scale ranging from "not at all" (0) to "extremely" (4).
The POMS consists of 10 scales, which measure friendliness, anxiety, depression, fatigue, anger, elation, confusion, vigor, arousal, and positive mood.
|
Week 1, Week 2, Week 3, Week 4
|
Change from Baseline in Mood Assessed by the Positive and Negative Affect Scale (PANAS)
Time Frame: Week 1, Week 2, Week 3, Week 4
|
The PANAS is a 20-item self-report scale in which mood variables are rated by subjects on a 1-5 scale (from very slightly/not at all to extremely), based on how they feel.
Ten PANAS items rate positive affect (PA), that is, the extent to which a person feels enthusiastic, active, and alert; ten items rate negative affect (NA), that is, the extent to which a person is experiencing subjective distress and aversive mood states.
|
Week 1, Week 2, Week 3, Week 4
|
Change from Baseline in Quality of Life Measured by the 36-Item Short Form (SF-36)
Time Frame: Week 1, Week 4
|
The SF-36 is a multi-purpose, 36-item short-form health survey that gives an 8-scale profile of functional health and well-being scores (higher scores indicate better quality of life).
|
Week 1, Week 4
|
Change from Baseline in Sexual Health Measured by the Arizona Sexual Experience Scale (ASEX)
Time Frame: Week 1, Week 4
|
The ASEX contains 5 items designed to assess sexual health and sexual dysfunction.
The scale contains both a male and female version, with only one question different.
Each item is scored on a scale from 1-6, with higher scores indicating increased dysfunction.
|
Week 1, Week 4
|
Patient's Global Impression of Change (PGIC) Scale Score at Week 4
Time Frame: Week 4
|
The PGIC is a single-question, 7-point scale depicting a patient's rating of overall improvement from "very much worse" to "very much improved".
|
Week 4
|
Change from Baseline on Stroop Color-Word Test
Time Frame: Week 1, Week 4
|
This test measures the ability to inhibit inappropriate responses and resist interference.
Increased errors and time to complete the test reflect poorer performance.
|
Week 1, Week 4
|
Change from Baseline on Trail Making Test
Time Frame: Week 1, Week 4
|
This test is designed to measure visual conceptual and visuomotor tracking, as well as maintenance of cognitive set.
Increased errors and time to complete the test reflect poorer performance.
|
Week 1, Week 4
|
Change from Baseline on the Wisconsin Card Sort Test (WCST)
Time Frame: Week 1, Week 4
|
This test assesses a person's ability to form abstract concepts, utilize feedback, and to shift and maintain set.
Total number of categories correct, perseverative and other error types are calculated, with increased errors and decreased number of categories correct indicating poorer performance.
|
Week 1, Week 4
|
Change from Baseline on the Multi-Source Interference Task (MSIT)
Time Frame: Week 1, Week 4
|
This test assesses a person's ability to ignore distracting stimuli and identify the correct item.
Increased numbers of errors indicate poorer performance.
|
Week 1, Week 4
|
Change from Baseline on the Letter-Number Sequencing (LNS) Subtest of the Wechsler Adult Intelligence Scale
Time Frame: Week 1, Week 4
|
This subtest is designed to assess working memory and primarily measures the efficiency of attention, concentration and mental control.
Higher scores reflect better performance.
|
Week 1, Week 4
|
Change from Baseline on the Digit Symbol Substitution Test (DSST) of the Wechsler Adult Intelligence Scale
Time Frame: Week 1, Week 4
|
The DSST measures attention, psychomotor speed, visual scanning and information processing.
Higher scores reflect better performance.
|
Week 1, Week 4
|
Change from Baseline on the Controlled Oral Word Association Test (COWAT)
Time Frame: Week 1, Week 4
|
This test measures the subject's ability to produce individual words under restricted conditions, and interrogates both executive function and verbal memory.
Performance is measured by an age and education corrected total of the number of words generated for each section, with higher numbers indicating better performance.
|
Week 1, Week 4
|
Change from Baseline on the Rey Auditory Verbal Learning Test (RAVLT)
Time Frame: Week 1, Week 4
|
This verbal learning test assesses the subject's immediate and delayed recall.
Higher scores reflect better performance.
|
Week 1, Week 4
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Staci Gruber, PhD., McLean Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015P000959
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on Full-Spectrum Cannabidiol
-
Formula30A LLCCompletedGeneralized Anxiety DisorderUnited States, Puerto Rico
-
Colorado State UniversityNaturex-DbsCompletedAging | Endothelial DysfunctionUnited States
-
Gaia Herbs Inc.Appalachian College of PharmacyCompleted
-
University of BergenCompletedSleep | Circadian Rhythm Sleep Disorder, Delayed Sleep PhaseNorway
-
University of Texas at AustinWay West Wellness; SunFlora.IncSuspendedAnger | Sleep Disturbance | Anxiety Depression | Substance Abuse | Alcohol Abuse | Stress ReactionUnited States
-
Fenix Innovation GroupMonash Health; Neurotech InternationalNot yet recruitingAutism Spectrum DisorderAustralia
-
Charlotte's Web, IncUnknownAcne Vulgaris | Acne Vulgaris Superficial Mixed Comedonal and Inflammatory
-
Brigham and Women's HospitalHarvard Medical School (HMS and HSDM)CompletedOpioid-use DisorderUnited States
-
Finch Research and Development LLC.CompletedClostridium Difficile Infection RecurrenceCanada, United States
-
Finch Research and Development LLC.Medpace, Inc.CompletedClostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal TransplantUnited States, Canada